Article
The interaction between androgen receptor and semenogelin I: a synthetic LxxLL peptide antagonist inhibits the growth of prostate cancer cells.
British journal of cancer - 6 Feb 2018
Li Peng, Chen Jinbo, Kashiwagi Eiji, Mizushima Taichi, Han Bin, Inoue Satoshi, Ide Hiroki, Izumi Koji, Miyamoto Hiroshi
Abstract excerpt
BACKGROUND: We previously demonstrated that a seminal plasma protein, semenogelin I (SgI), functioned as an androgen receptor (AR) coactivator. Meanwhile, several short sequence motifs in AR coregulators, such as LxxLL (L=leucine), have been shown to mediate specific interactions with AR. METHODS: We investigated the role of the LxxLL motif within SgI in the interactions with AR and cell growth in prostate cancer...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.